Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic test
Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic test"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild cognitive impairment,
without a genetic test. US researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, should not be prescribed for people with mild
cognitive impairment, without a genetic test. Researchers from the University Of California discovered that for people who carry a specific genetic variation, the K-variant of
butyrylcholinesterase, or BChE-K donezpezil, could accelerate cognitive decline. The study has been published in Journal of Alzheimer's Disease. Mild cognitive impairment is a
transitional state between normal age-related changes in cognition and dementia. Because many people with the condition display symptoms similar to those caused by Alzheimer's disease,
some physicians prescribe donepezil, which is marketed under the brand name Donepezil was tested as a possible treatment for mild cognitive impairment in a large, federally funded study
published in 2005, but it was not approved by the FDA. Still, doctors have often prescribed the drug "off-label" -- meaning that it is not approved for that specific disorder --
for their patients with mild cognitive impairment. The researchers looked at the association between BChE-K and changes in cognitive function. Using two tests that measure cognitive
impairment, the Mini-Mental State Examination and the Clinical Dementia Rating Sum of Boxes. The findings indicated that people with the genetic variation, who were treated with donepezil
had greater changes in their scores than those who took placebos. They also found that those who took donepezil had a faster cognitive decline than those who took the placebo. The findings
reinforce the importance of physicians discussing the possible benefits and risks of this treatment with their patients. (This article has not been edited by DNA's editorial team and is
auto-generated from an agency feed.)
Trending News
Janie BrownTwenty years after my father's terminal cancer diagnosis, I listened to my spouse's doctor reveal the same new...
Game night entertaining made easyKEEP DRINKS SIMPLE Of course, you’ll want to serve a few drinks along with these snacks, but don’t make it overly compli...
The plastic littering a beach can be tracked to its source* RESEARCH HIGHLIGHT * 15 February 2022 Efforts to clean up beaches could be aided by a model that traces the movement o...
Evolution of darwin’s finches and their beaks revealed by genome sequencingABSTRACT Darwin’s finches, inhabiting the Galápagos archipelago and Cocos Island, constitute an iconic model for studies...
The metatron: an experimental system to study dispersal and metaecosystems for terrestrial organismsABSTRACT Dispersal of organisms generates gene flow between populations. Identifying factors that influence dispersal wi...
Latests News
Alzheimer's drug shouldn't be prescribed for cognitive impairment, without genetic testUS researchers have warned, Donepezil, a medication that is approved to treat people with Alzheimer's disease, shou...
Iran's nuclear plans | NatureDo a satellite launch and a tonne of enriched uranium add up to an arsenal? Access through your institution Buy or subsc...
From garlic to mashed potato: france's huge food record-breakersFOOD IS SACRED IN FRANCE SO NO WONDER CHEFS, TOWNS AND FESTIVALS WANT A PLACE IN THE RECORD BOOKS FOR THEIR CULINARY CRE...
Building affordable housing first, west sacramento, california - aarpMemorial Day Sale! Join AARP for just $11 per year with a 5-year membership Join now and get a FREE gift. Expires 6/4 G...
The page you were looking for doesn't exist.You may have mistyped the address or the page may have moved.By proceeding, you agree to our Terms & Conditions and our ...